Perioperative administration of cyclooxygenase-2 inhibitors reduces pain in TKA patients .
OrthoEvidence Journal (OE Journal) - ACE Report
OE Journal. 2013;1(3):18 J Arthroplasty. 2013 Feb;28(2):207-213.e2. doi: 10.1016/j.arth.2012.04.008. Epub 2012 Jun 78 studies (571 patients) were analyzed to evaluate the postoperative effects of selective cyclooxygenase-2 (COX-2) inhibitors when administered to patients during TKA. Results indicated that COX-2 inhibitors administered during TKA resulted in reduced postoperative pain, opioid consumption, and incidence of complications. Blood loss during the first 24 hours following surgery did not differ between patients who received COX-2 inhibitors compared to a control. It should be noted that selective COX-2 inhibitors have been associated with an increased risk of myocardial infarction and rofecoxib, a drug used in three of the included studies has been removed from the market.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
Are you affiliated with one of our partner associations?
Click here to gain complimentary access as part your association member benefits!
0 of 4 monthly FREE articles unlocked
